Multiple myeloma (MM) is a life-threatening plasma cell malignancy. MM has a prolonged clinically detectable premalignant phase called monoclonal gammopathy of undetermined significance (MGUS) that can be identified by detection of the secreted monoclonal immunoglobulin (M protein) and through the presence of an abnormal immunoglobulin kappa/lambda free light chain (FLC) ratio. Over the last 10 years we have extensively characterized the various precursor stages of MM, and conducted numerous studies establishing monoclonal elevations of FLC and abnormalities in the FLC ratio as biomarkers for diagnosis, prognosis, response assessment, and risk stratification across a spectrum of plasma cell disorders. One of the goals of this renewal is to determine why MGUS occurs, and whether polyclonal plasma cell proliferation in response to infection or inflammation plays a role in pathogenesis of MGUS, MM and related malignancies. We are also investigating the reasons for dramatic racial disparity in incidence of MM;young blacks for example have a 3-fold higher risk than whites. Our studies show that a major reason for the racial discrepancy is a marked excess in the incidence of the precursor MGUS phase in blacks. Similarly, we have uncovered a significant familial predisposition in MGUS and MM. Since MM consists of multiple unique entities from a cytogenetic standpoint, we need to determine the precise cytogenetic subtypes responsible for racial disparity and familial predisposition. Thus two fundamental questions are: 1) Can we identify biomarkers that predict risk of MM prior to the premalignant MGUS stage (precursor of the precursor stage)? 2) What are the specific cytogenetic subtypes that account for the increased risk of MM in blacks and in first degree-relatives? In Aim 1 we will determine if polyclonal elevations of serum immunoglobulin FLC are associated with an increased risk of MGUS, MM and related B cell malignancies in a large cohort of nearly 16,000 patients.
In Aim 2 we will assemble and study a cohort of 800 blacks with MM to identify the specific cytogenetic subtype(s) of MM associated with increased risk of MM, and also identify predictors of response to therapy and survival.
In Aim 3 we will conduct studies to identify the specific cytogenetic subtypes associated with familial predisposition in MGUS. We believe our studies are highly innovative, and will have a far-reaching impact on our understanding of the etiology of MGUS, and the cytogenetic basis for racial disparity and familial predisposition. Our studies will result in a promising biomarker to identify patients at high risk for MM and related malignancies in the general population.
Aims 2 and 3 will have a major impact on the management of patients with MGUS and MM, especially African Americans and first-degree relatives or persons with MGUS.
Multiple myeloma (MM) is a life-threatening plasma cell malignancy that is always preceded by a prolonged premalignant phase called monoclonal gammopathy of undetermined significance (MGUS). We need to determine why MGUS occurs, and whether polyclonal plasma cell proliferation in response to infection or inflammation plays a role in pathogenesis of MGUS, MM, and related malignancies. We also need to determine the cytogenetic basis for the marked racial disparity and familial predisposition seen in MM and MGUS.
|Gonsalves, Wilson I; Morice, William G; Rajkumar, Vincent et al. (2014) Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol 167:500-5|
|Greenberg, A J; Rajkumar, S V; Therneau, T M et al. (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28:398-403|
|Landgren, O; Graubard, B I; Katzmann, J A et al. (2014) Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537-42|
|Kyle, Robert A; Larson, Dirk R; Therneau, Terry M et al. (2014) Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 1:e28-e36|
|Kumar, S K; Dispenzieri, A; Lacy, M Q et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122-8|
|Ramakrishnan, V; Painuly, U; Kimlinger, T et al. (2014) Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia 28:1519-28|
|Gonsalves, Wilson I; Rajkumar, S Vincent; Go, Ronald S et al. (2014) Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 124:907-12|
|Gonsalves, W I; Rajkumar, S V; Gupta, V et al. (2014) Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 28:2060-5|
|Bergsagel, P Leif; Mateos, Maria-Victoria; Gutierrez, Norma C et al. (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121:884-92|
|Rajkumar, S V; Gupta, V; Fonseca, R et al. (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738-44|
Showing the most recent 10 out of 97 publications